Mayo Clinic Laboratories > Neurology

PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Case Study Promoting laboratory stewardship through clinical decision support
Eye on Innovation New test distinguishes between prion disease and other causes of rapidly progressive dementia
Patient Spotlight Innovative SORD test provides clarity for two young patients
Patient Spotlight Rare patient case helps inform and validate GABA-A-R antibody encephalitis testing: JoAnne Michael
Answers From the Lab Tests Aid Diagnosis of Cancer-Associated Neurological Disorders

NEUROLOGY TEST SPECIALTIES

Autoimmune disorders Autoimmune disorders
Autoimmune disorders

Covering the spectrum of autoimmune neurological disorders, our evaluations apply a phenotype-specific approach to diagnose and guide treatment for patients affected by immune-mediated neurological illness.

Biopharma testing Biopharma testing
Biopharma testing

With 19 subspecialty labs that perform neurology testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our menu, including testing for Alzheimer’s disease, dementia, and autoimmune conditions, provides partners with results that move solutions through the development pipeline.

Demyelinating disease Demyelinating disease
demyelinating disease

We offer sensitive and specific testing to diagnose a range of demyelinating diseases, from classic multiple sclerosis (MS) to atypical MS, AQP4/MOG-associated disorders, and spinal cord disorders.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Epilepsy Epilepsy
Epilepsy

We offer testing that identifies genetic and autoimmune causes of epilepsy. With testing developed by neurologists, epileptologists, and geneticists, physicians can determine the causes of epilepsy in their patients and identify potential treatment options.

Movement disorders Movement disorders
Movement disorders

Our comprehensive movement disorder testing includes an autoimmune movement disorders panel that contains the latest newly discovered clinically actionable antibodies. We also offer hereditary movement disorders testing that covers ataxia, Huntington's disease, Parkinson's disease, and more.  

Neurogenetics Neurogenetics
Neurogenetics

A multidisciplinary team of clinical neurology experts, laboratory scientists, and genetic counselors work collaboratively to develop and implement our neurogenetic testing. Covering the full range of neurogenetic illness, our testing is unparalleled in scope and detail and uses an algorithmic and phenotypic approach that ensures the right patient receives the right test at the right time.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our comprehensive menu of precision testing enables physicians to diagnose and manage patients with disorders such as myasthenia gravis, Lambert-Eaton syndrome, immune-mediated necrotizing myopathy, hereditary myopathy, and more.

Pediatrics Pediatrics
Pediatrics

Including evaluations for autoimmune central nervous system disorders, multiple sclerosis, and narcolepsy, our data-driven pediatric testing provides precision results to guide treatment and place young patients on the path to healing.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

We offer testing to identify peripheral autoimmune neuropathy with axonal or demyelinating causes, as well as next-generation sequencing to help establish whether a peripheral neuropathy is genetic in nature.

“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”

John Mills, Ph.D., co-director, Neuroimmunology Laboratory

OUR DIFFERENCE

Clinically driven neurology test menu
Consolidate more of your sendout testing to one trusted lab.

Solving the most complex neurologic cases
We continually innovate to develop new testing approaches that enable answers to the rarest and most complex neurological conditions.

Backed by the world’s leading experts
Our laboratories are led by clinical neurologists who have extensive experience using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.

News and updates

The latest

Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

Learn more
Neurofilament light chain: Bjorn Oskarsson, M.D.

In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.

Visit Mayo Clinic Laboratories at the American Academy of Neurology Annual Meeting 2023

Mayo Clinic Laboratories is thrilled to participate in the American Academy of Neurology Annual Meeting 2023.

Test assesses all inherited Parkinson’s disease genes:  Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D.

Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.

Neuromuscular gene panel provides comprehensive analysis: Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D.

Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs diagnosis and treatment. The phenotype-based panel covers the complete list of neuromuscular genes and their variants.

Neuropathy and Neuromuscular Gene Panel Update

In this month's "Hot Topic," Christopher Klein, M.D., and Zhiyv (Neal) Niu, Ph.D., discuss how Mayo Clinic’s neuropathy and neuromuscular gene panels have enhanced patient care.

Whole genome sequencing streamlines diagnosis

Nicole Boczek, Ph.D., and Sarah Barnett, M.S., CGC, explain how Mayo Clinic Laboratories' whole genome sequencing provides comprehensive information for rapid diagnosis of hereditary disorders.

Chromosomal microarray better informs brain tumor diagnosis

Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.

Autoimmune Encephalitis Misdiagnosis  

In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.

Lab discoveries fuel updates for autoimmune movement disorders test

Mayo Clinic Laboratories expanded movement disorders panel better identifies autoimmune conditions. Four recently identified biomarkers — septin-5, septin-7, neurochondrin, and adaptor protein-3B2 — have been added to the panel, and all four have been shown to respond to immunotherapy.

Novel biomarkers added to movement disorders profile

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

Autoimmune Encephalitis Diagnosis and Misdiagnosis

PACEIn this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.

Eoin Flanagan, M.B., B.Ch., explains autoimmune encephalitis misdiagnosis in JAMA Neurology

Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.

View More
Resources
Download Neurology test request form
Delivering specialized testing and consultative support for:
Learn more Commercial laboratories
Learn more Global healthcare
Learn more Hospitals and health systems

LEARN MORE ABOUT HOW WE CAN BUILD YOUR LAB'S POTENTIAL.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.